Welcome to our dedicated page for Evolent Health news (Ticker: EVH), a resource for investors and traders seeking the latest updates and insights on Evolent Health stock.
Evolent Health Inc (NYSE: EVH) delivers transformative healthcare solutions through value-based care models and AI-powered technology. This news hub provides investors and healthcare professionals with essential updates on the company developments shaping modern care delivery.
Access authoritative coverage of EVH's strategic initiatives including specialty care management advancements, AI-driven clinical review systems, and partnerships with major health systems. Our curated news collection features earnings reports, regulatory filings, and analysis of operational milestones in oncology, cardiology, and musculoskeletal care management.
Key focus areas include updates on Evolent's proprietary platforms for total cost of care optimization, health plan administration innovations, and value-based payment model expansions. Stay informed about technological integrations like the Machinify Auth AI system that streamline clinical decision-making processes.
Bookmark this page for real-time updates on EVH's progress in aligning financial incentives with patient outcomes. Monitor how their integrated approach to population health management continues to redefine care delivery standards across healthcare networks.
Evolent Health, Inc. (EVH) reported a robust third quarter for 2022, generating $352.6 million in revenue, a 58.5% increase year-over-year. The company achieved a net income of $2.1 million with a margin of 0.6%, alongside an Adjusted EBITDA of $28.1 million and an 8.0% margin. Total lives on the platform reached 19.5 million. Evolent's new partnerships and acquisitions reflect sustained growth and innovation. For Q4 2022, revenue is projected between $361.0 million and $381.0 million, with full-year revenue guidance of $1.33 billion to $1.35 billion.
Evolent Health, Inc. (NYSE: EVH) has announced it will release its third quarter 2022 operating results on November 2, 2022, after market close. A conference call will follow at 5:00 p.m. Eastern Time. Interested parties can join the call by dialing 855.940.9467 or 412.317.6034 for international access. An audio playback will be available on Evolent's investor relations website for 90 days post-call. Evolent Health focuses on delivering clinical and administrative solutions to improve healthcare efficiency and affordability.
Evolent Health (NYSE: EVH) announced participation in several investor conferences. CFO John Johnson and VP Investor Relations Seth Frank will present at the Wells Fargo Healthcare Conference on September 9, 2022, at 10:25 a.m. ET in Everett, MA. They will also conduct meetings at the Baird 2022 Global Healthcare Conference on September 13, 2022. Additionally, Frank will take part in the BofA Securities 2022 Healthcare Innovation Forum on September 29, 2022, with further details to be shared on the company's Investor Relations website. Webcast links will be available online.
Evolent Health (NYSE: EVH) announced Dan McCarthy's appointment as President, effective September 15, 2022. McCarthy, formerly CEO of New Century Health, will lead value-based specialty operations and oversee the integration of recent acquisitions into Evolent's platform. Frank J. Williams, co-founder and former CEO, will not seek re-election to the Board in June 2023. Both leaders emphasize a commitment to a seamless transition and continued growth.
Evolent Health, Inc. (NYSE: EVH) will participate in the Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022, at 4:30 p.m. ET. CEO Seth Blackley and VP of Investor Relations Seth Frank will lead investor meetings and present at the event held in Boston, Massachusetts.
A live audio webcast will be accessible on Evolent's Investor Relations website.
Evolent Health provides clinical solutions aimed at improving health care delivery.
Evolent Health, Inc. (EVH) reported Q2 2022 revenue of $319.9 million, a 44.1% increase year-over-year. The net loss was $4.6 million, improving from a $9.1 million loss in Q2 2021. Adjusted EBITDA reached $21.7 million, reflecting a margin of 6.8%. The company added 10 new operating partnerships in 2022, exceeding its goal. Total Lives on Platform reached 21.9 million. For Q3, revenue guidance is set between $343.0 million and $363.0 million. Full-year revenue is projected to be $1.32 billion to $1.36 billion.
Evolent Health (NYSE: EVH) will report its second quarter 2022 operating results on August 2, 2022, post-market. A conference call is scheduled at 5:00 p.m. Eastern Time where interested parties can join by calling 855.940.9467 or 412.317.6034. An audio replay will be accessible on the company’s investor relations website for 90 days. Evolent Health is known for its clinical and administrative solutions aimed at improving health care affordability and efficiency, and serves a national client base among leading payers and providers.
Evolent Health has announced a definitive agreement to acquire IPG, a provider of surgical management solutions for musculoskeletal conditions, for $375 million plus up to $87 million in contingent consideration. The acquisition aims to enhance Evolent's position in value-based specialty care and is expected to be immediately accretive to Adjusted EBITDA margins and cash flow. The integration will diversify Evolent’s customer mix and provide valuable relationships with national commercial health plans.
Evolent Health, Inc. (NYSE: EVH) has announced that its CEO Seth Blackley, CFO John Johnson, and VP of Investor Relations Seth Frank will participate in several investor conferences in May and June 2022. The events include presentations at the BofA Securities Health Care Conference on May 12, RBC Capital Markets Global Healthcare Conference on May 17, and the 42nd Annual Growth Stock Conference on June 6. Additionally, Johnson and Frank will attend the J.P. Morgan Healthcare Services Summit on June 21, which will not be webcasted. Live webcasts will be available on the company's Investor Relations website.
